Aerpio Asset AKB-9778 Fails to Hit Endpoints in Phase IIb Diabetic Retinopathy Trial

Aerpio said the Phase IIb asset did show some positive data in a number of pre-specified secondary endpoints, including changes in Urine Albumin-Creatinine Ratio, a measure of kidney function, and in intraocular pressure.